144 related articles for article (PubMed ID: 19404557)
1. Competition of unfractionated heparin and idraparinux on activated partial thromboplastin time and effect of exogenous antithrombin.
Gouin-Thibault I; Samama MM
Thromb Haemost; 2009 May; 101(5):986-7. PubMed ID: 19404557
[No Abstract] [Full Text] [Related]
2. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
[No Abstract] [Full Text] [Related]
3. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
Marlar RA; Clement B; Gausman J
Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
[TBL] [Abstract][Full Text] [Related]
4. Anticoagulant effect of unfractionated heparin in antithrombin-depleted plasma in vitro.
Krulder JW; Strebus AF; Meinders AE; Briët E
Haemostasis; 1996; 26(2):85-9. PubMed ID: 9119287
[TBL] [Abstract][Full Text] [Related]
5. Performance of Activated Partial Thromboplastin Time (APTT): Determining Reagent Sensitivity to Factor Deficiencies, Heparin, and Lupus Anticoagulants.
Kershaw G
Methods Mol Biol; 2017; 1646():75-83. PubMed ID: 28804819
[TBL] [Abstract][Full Text] [Related]
6. Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy.
Lawlor M; Gupta A; Ranard LS; Madhavan MV; Li J; Eisenberger A; Parikh SA; Sethi SS; Masoumi A
Thromb Res; 2021 Feb; 198():79-82. PubMed ID: 33302210
[TBL] [Abstract][Full Text] [Related]
7. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
8. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
[TBL] [Abstract][Full Text] [Related]
9. Activated Partial Thromboplastin Time versus Anti-Factor Xa Levels for Monitoring Unfractionated Heparin Therapy in Children: An Institutional Experience.
Woods GM; Stanek J; Harrison S; Texter K; Kerlin BA; Dunn AL; Kumar R
J Pediatr Hematol Oncol; 2017 Oct; 39(7):576-577. PubMed ID: 28902081
[No Abstract] [Full Text] [Related]
10. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
[TBL] [Abstract][Full Text] [Related]
11. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of antithrombin-dependent anticoagulants through clot waveform analysis to potentially distinguish them from antithrombin-independent inhibitors targeting activated coagulation factors.
Wakui M; Fujimori Y; Nakamura S; Oka S; Ozaki Y; Kondo Y; Nakagawa T; Katagiri H; Murata M
J Clin Pathol; 2021 Apr; 74(4):251-256. PubMed ID: 32796051
[TBL] [Abstract][Full Text] [Related]
13. Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase.
Anderson JA; Fredenburgh JC; Stafford AR; Guo YS; Hirsh J; Ghazarossian V; Weitz JI
J Biol Chem; 2001 Mar; 276(13):9755-61. PubMed ID: 11134031
[TBL] [Abstract][Full Text] [Related]
14. From Activated Partial Thromboplastin Time to Antifactor Xa and Back Again.
May JE; Siniard RC; Taylor LJ; Marques MB; Gangaraju R
Am J Clin Pathol; 2022 Mar; 157(3):321-327. PubMed ID: 34562001
[TBL] [Abstract][Full Text] [Related]
15. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
16. The antiheparin effect of alpha 1-acid glycoprotein, evaluated by the activated partial thromboplastin time and by a factor Xa assay for heparin.
Andersen P
Haemostasis; 1980; 9(5):303-9. PubMed ID: 7409614
[TBL] [Abstract][Full Text] [Related]
17. How to use unfractionated heparin to treat neonatal thrombosis in clinical practice.
Bhatt MD; Paes BA; Chan AK
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):605-14. PubMed ID: 26656898
[TBL] [Abstract][Full Text] [Related]
18. Antithrombin concentrate in pediatric patients requiring unfractionated heparin anticoagulation: a retrospective cohort study.
Ryerson LM; Bauman ME; Kuhle S; Bruce AA; Massicotte MP
Pediatr Crit Care Med; 2014 Oct; 15(8):e340-6. PubMed ID: 24901804
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides.
Wall D; Douglas S; Ferro V; Cowden W; Parish C
Thromb Res; 2001 Aug; 103(4):325-35. PubMed ID: 11562342
[TBL] [Abstract][Full Text] [Related]
20. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
Vandiver JW; Vondracek TG
Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
